Stay updated with breaking news from Named Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive results on primary and secondary endpoints, identifying dose for future development Direct and significant effect of CER-001 on endotoxin removal and consequent reduction in the inflammatory
ABIONYX Pharma: ABIONYX Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury Temporary Authorization for Named Use (ATUn) showed promising efficacy in renal diseases Evaluation of the clinical activity by dosage level of CER-001 in the prevention of Acute Kidney Injury in ICU patients with septicemia A potentially modifying effect on the progression of the inflammatory cascade in sepsis Pending positive data, the company aims to move into Phase 2b by end of 2021 Regulatory News: ABIONYX Pharma ( FR0012616852 ABNX PEA PME eligible),...